Loading
Life sciences · Journal article
Cns Oncology · August 3, 2026
A consensus or society position rather than new primary data.
This is a narrative review summarizing clinical management practices and evidence for BRAF inhibitors in both pediatric and adult gliomas. It provides practical guidance on toxicity management, mutation-specific therapy selection, and emerging resistance-overcoming strategies, but does not report new efficacy or safety outcome data.
Journal article. Patients with BRAF-altered high-grade glioma (HGG) and low-grade glioma (LGG), including both pediatric and adult populations.
Dabrafenib combined with trametinib is FDA-approved for BRAF V600E-mutant gliomas Tovorafenib is approved for pediatric low-grade gliomas harboring BRAF V600 mutations or BRAF fusions Pediatric low-grade glioma patients often experience durable responses to BRAF inhibitors
No original efficacy or safety data reported; based on published literature synthesis Specific response rates, progression-free survival, or adverse event frequencies not stated
Clinicians treating BRAF-altered gliomas should tailor therapy selection to the specific BRAF alteration, implement proactive toxicity management and dose reduction where needed, and consider emerging combination strategies or next-generation inhibitors when resistance develops.
A narrative review synthesizing clinical best practices and evidence for BRAF inhibitor use in glioma, offering practical management guidance but not reporting new primary efficacy or safety data.
As stated by the source record.
Clinicians treating BRAF-altered gliomas should tailor therapy selection to the specific BRAF alteration, implement proactive toxicity management and dose reduction where needed, and consider emerging combination strategies or next-generation inhibitors when resistance develops.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
BRAF inhibitors have advanced treatment for patients with BRAF-altered high and low-grade glioma (HGG and LGG, respectively). Clinically-available therapies are effective but require selection by mutation type and careful, proactive toxicity management to maximize patient quality of life and treatment duration. While pediatric LGG patients often experience durable responses, adults with LGG and patients with HGG frequently develop treatment resistance and disease progression while on treatment. Strategies to prevent or overcome resistant disease are under active preclinical and clinical investigation. This review serves as a primer to BRAF-altered therapy in glioma, outlines best practices for using available BRAF inhibitors, and highlights emerging therapeutic approaches aimed at improving outcomes in resistant disease. It serves as a forward-looking, practical guide for clinicians treating patients with BRAF-altered glioma.Article highlightsBRAF inhibitors are effective in both pediatric and adult low- and high-grade gliomas (LGG and HGG), but treatment should be tailored to the specific BRAF alteration (Table 1).Dabrafenib combined with trametinib is FDA-approved for BRAF V600E-mutant gliomas, while tovorafenib is approved for pediatric LGGs harboring BRAF V600 mutations or BRAF fusions.Proactive management, including anticipatory guidance and dose reduction for some patients, is essential to mitigate toxicity and avoid treatment interruptions.Tumor progression can occur during treatment interruptions or drug cessation; however, some patients may respond to BRAF inhibitor rechallenge.Emerging strategies focus on combination with other therapies including radiation, autophagy inhibitors, additional targeted agents, and others to overcome acquired resistance.Next-generation BRAF inhibitors-including paradox breakers, dimer disruptors, and protein degraders-are under clinical investigation (Table 2).
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.